References
- Summary of Product Characteristic – Physiotens 0.2 mg, Physiotens 0.3 mg, Physiotens 0.4 mg (Moxonidinum) (in Polish), The Office for Registration of Medicinal Products, Medical Devices and Biocidal Products Home Page, Poland. At http://www.urpl.gov.pl/rejestr//Physiotens02_03_04.pdf. Accessed 19 June 2008.
- J Webster, and HF Koch. Aspects of tolerability of centrally acting antihypertensive drugs. J Cardiovasc Pharmacol 1996; 27:49–54.
- DD Smyth, and SB Penner. Imidazoline receptor mediated natriuresis: central and/or peripheral effect?. J Auton Nerv Syst 1998; 72:155–162.
- HL Elliott. Moxonidine: pharmacology, clinical pharmacology and clinical profile. Blood Press 1998; 3:23–27.
- C Fenton, GM Keating, and KA Lyseng-Williamson. Moxonidine: a review of its use in essential hypertension. Drugs 2006; 66:477–496.
- M Schachter, J Luszick, B Jäger, C Verboom, and E Söhlke. Safety and tolerabilility of moxonidine in the treatment of hypertension. Drug Saf 1998; 19:191–203.
- GA Head, and DN Mayorov. Imidazoline receptors, novel agents and therapeutic potential. Cardiovasc Hematol Agents Med Chem 2006; 4:17–32.
- A Radwanska, and R Kaliszan. Comparative analysis of effects of imidazoline drugs on isolated rat heart atria. J Physiol Pharmacol 1993; 44:73–87.